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Small-cell lung cancers (SCLCs) initially respond to chemotherapy but are often resistant at recurrence. A potentially new method to
overcome resistance is to combine classical chemotherapeutic drugs with apoptosis induction via tumour necrosis factor (TNF) death
receptor family members such as Fas. The doxorubicin-resistant human SCLC cell line GLC4-Adr and its parental doxorubicin-
sensitive line GLC4 were used to analyse the potential of the Fas-mediated apoptotic pathway and the mitochondrial apoptotic
pathway to modulate doxorubicin resistance in SCLC. Western blotting showed that all proteins necessary for death-inducing
signalling complex formation and several inhibitors of apoptosis were expressed in both lines. The proapototic proteins Bid and
caspase-8, however, were higher expressed in GLC4-Adr. In addition, GLC4-Adr expressed more Fas (3.1x) at the cell membrane.
Both lines were resistant to anti-Fas antibody, but plus the protein synthesis inhibitor cycloheximide anti-Fas antibody induced 40%
apoptosis in GLC4-Adr. Indomethacin, which targets the mitochondrial apoptotic pathway, induced apoptosis in GLC4-Adr but not in
GLC4 cells. Surprisingly, in GLC4-Adr indomethacin induced caspase-8 and caspase-9 activation as well as Bid cleavage, while both
caspase-8 and caspase-9 specific inhibitors blocked indomethacin-induced apoptosis. In GLC4-Adr, doxorubicin plus indomethacin
resulted in elevated caspase activity and a 2.7-fold enhanced sensitivity to doxorubicin. In contrast, no effect of indomethacin on
doxorubicin sensitivity was observed in GLC4. Our findings show that indomethacin increases the cytotoxic activity of doxorubicin in
a doxorubicin-resistant SCLC cell line partly via the death receptor apoptosis pathway, independent of Fas.
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Lung cancer is the tumour type with the highest incidence in the
Western world. A total of 25% of lung cancers are of the small-cell
lung cancer (SCLC) type. These tumours are well known for their
initial sensitivity to chemotherapeutic agents and thereafter
frequently recur at which time the tumour is drug resistant
(Glisson, 2003). A common mechanism for drug resistance shared
by chemotherapeutic drugs is the failure of the tumour cells to go
into apoptosis. Interestingly, tumour cells have an independent
pathway available, which can be used to induce apoptosis, namely,
the death receptor ligand signalling pathway (Younes and Kadin,
2003). This has raised interest to exploit this pathway to
circumvent drug resistance. Fas and Fas ligand (FasL) belong to
the TNF family of death receptors and ligands (Trauth et al, 1989;
Itoh et al, 1991; Suda et al, 1993). Fas expression is present in
many tumours and tumour cell lines including in SCLC (Friesen
et al, 1997; Muller et al, 1997; Niehans et al, 1997; Fulda et al, 1998;
Kawasaki et al, 2000). After trimerisation of Fas on the cell
membrane by extracellular FasL (Huang et al, 1996),
Fas-associated Death Domain (FADD) and caspase-8 bind to the
intracellular death domains of Fas and induce a death signal in the
cell (Debatin et al, 1997). This leads to the activation of a cascade
of caspases and eventually to cell death. In addition, several
antiapoptosis proteins regulate the Fas-mediated death pathway.
Important antiapoptosis proteins are decoy receptor 3 (DcR3),
Fas-associated phosphatase-1 (FAP-1), the long and short isoform
of FLICE-inhibitory protein (FLIP1 and FLIPS) and the inhibitors
of apoptosis family (IAPs) (Sato et al, 1995; Deveraux et al, 1997;
Yanagisawa et al, 1997; Pitti et al, 1998; Li et al, 2000).
There is an alternative pathway for death receptor-induced
apoptosis that involves the mitochondria (Scaffidi et al 1998,
1999). This pathway is controlled by proapoptotic and antiapop-
totic proteins from the Bcl-2 family. One of the key proapoptotic
proteins in this pathway is Bid. When caspase-8 is activated in the
initial phase of death receptor-induced apoptosis, it can cleave Bid.
The p15 form of truncated Bid (tBid) translocates to the
mitochondria where cytochrome c is released. Cytochrome
c activates caspase-9, which activates downstream effector caspases
resulting in apoptosis (Luo et al, 1998).
In several tumour cell lines, including SCLC cell lines, Fas
membrane expression is upregulated after exposure to chemother-
apeutic agents (Friesen et al, 1999). This can enhance sensitivity to
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sapoptosis-inducing anti-Fas antibody. Therefore, induction of
Fas-mediated apoptosis together with chemotherapy may be an
option to overcome drug resistance. At the moment, the major
problem of FasL or stimulating anti-Fas antibody is the liver
toxicity observed in mice (Ogasawara et al, 1993). However, several
attempts are ongoing to circumvent liver toxicity.
Another option to modulate drug resistance is the inhibition of
expression of antiapoptotic members of the Bcl-2 family of
apoptosis with nonsteroidal anti-inflammatory drugs (NSAIDs).
These drugs act by cyclooxygenase (COX) inhibition but can also
affect death receptor-mediated apoptosis pathways (Bagrij et al,
2001) and induce apoptosis by downregulation of Bcl-2 family
members (Liu et al, 1998, Crosby and DuBois, 2003). In SCLC cell
lines, Bcl-2 family members have been described as important
factors in chemotherapeutic drug resistance and therefore down-
regulation of Bcl-2 family members with an NSAID can be an
interesting modality to circumvent drug resistance (Sartorius and
Krammer, 2002). Human lung adenocarcinoma cells, exposed to
NSAIDs showed an effective reduction of the antiapoptosis Bcl-2
family member Mcl-1 (Lin et al, 2001).
In this study, we investigated the possibility of utilising the Fas-
mediated apoptosis route and indomethacin to modulate doxo-
rubicin resistance in an acquired doxorubicin resistant SCLC cell
line.
MATERIALS AND METHODS
Cell lines
GLC4 was derived from a pleural effusion in our laboratory and
kept in culture in RPMI 1640 medium supplemented with 10% heat
inactivated fetal calf serum (FCS) (both from Life Technologies,
Breda, The Netherlands). GLC4-Adr obtained resistance to
doxorubicin, but also to a wide range of other chemotherapeutic
agents, by stepwise increasing concentrations of doxorubicin
(Zijlstra et al, 1987; de Jong et al, 1990; Meijer et al, 1991;
Versantvoort et al, 1995). GLC4-Adr is 190.6716.2 times more
resistant to doxorubicin than its parental cell line. The doxorubicin
resistance in GLC4-Adr is due to a downregulation of the activity of
DNA-topoisomerase II (TOPO II) and amplification and over-
expression of the MRP-1 gene GLC4-Adr was exposed to 1.2mM
doxorubicin twice weekly. GLC4-Adr was cultured without
doxorubicin for 20 days prior to experiments. Cells were incubated
at 371C in a humidified atmosphere with 5% CO2. Cells from
exponentially growing cultures were used for all experiments.
Antibodies and reagents
The antibodies used for Western blot analysis were all diluted in
Tris buffered saline (TBS) buffer (20mM Tris-HCl, 137mM NaCl2
and 0.05% Tween 20) supplemented with 5% skim milk powder
(Merck, Darmstadt, Germany). The anti-FasL-, FADD- and XIAP
antibody were purchased from Transduction Laboratories (Alphen
a/d Rijn, the Netherlands), the Fas-, Bax-, Bcl-2-, Bcl-XS/L- and
FAP-1 antibody from Santa Cruz (Heerhugowaard, the Nether-
lands), the caspase-8 antibody from Cell Signalling (Leusden, the
Netherlands). The caspase-9, caspase-3- and FLIP antibody were
obtained from Pharmingen (Alphen a/d Rijn, the Netherlands).
The Mcl-1 antibody was purchased from DAKO (Glostrup,
Denmark). The Bid antibody was kindly provided by Dr J Borst,
the Netherlands Cancer Institute, Amsterdam. The PARP antibody
was obtained from Roche (Almere, the Netherlands) and the COX-
2 antibody was obtained from Cayman Chemical (Veenendaal, the
Netherlands). The anti-mouse secondary antibody was a horse-
radish peroxidase-labelled rabbit anti-mouse, which was diluted
1:1500 in TBS supplemented with 5% milk. The secondary anti-
rabbit antibody, a swine anti-rabbit, was diluted 1:1500. Against
goat primary antibodies, a rabbit anti-goat horseradish
peroxidase-labelled antibody 1:2000 was used. The fluorescein
(FITC) coupled rabbit anti-mouse antibody was diluted 1:20. All
secondary antibodies were purchased from DAKO (Glostrup,
Denmark). The proapoptotic mouse anti-Fas antibody 7C11 was
obtained from Immunotech (Versailles, France) and the phycoer-
ythrin (PE)-labelled anti-human Fas DX2 and the anti-FasL
antibody NOK-1 antibody from Pharmingen, Alphen a/d Rijn,
the Netherlands. The mouse monoclonal CH11 anti-Fas antibody
(Upstate Biotechnology, Veenendaal, The Netherlands) was used
for confocal laser microscopy. Doxorubicin was obtained from
Pharmacia Upjohn (Woerden, The Netherlands). Indomethacin
was purchased from ICN Biomedicals (Aurora, OH, USA), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT),
cycloheximide from Sigma Aldrich (Zwijndrecht, The Nether-
lands), Ponceau S from Sigma-Aldrich and Coomassie blue
solution was purchased from Biorad (Veenendaal, The Nether-
lands). MK-571 was purchased from Merck Sharp (Kirkland,
Canada)
SDS gel electrophoresis and Western blot
Proteins for Western blot analysis were extracted by lysing cells
with sample buffer containing 0.125 M Tris-HCl, 2% SDS, 10%
glycerol and 0.001% bromophenol blue. Samples were boiled for
5min. An amount of 10mg protein was run on 10% SDS
polyacrylamide gels at 200V and transblotted onto polyvinylidene
difluoride membranes (PVDF) (Millipore, Bedford, UK) with a
semi-dry blot system. Equal protein loading was confirmed by
Ponceau red staining of membranes and Coomassie blue staining
of the gels. Membranes were activated in methanol for 5min and
washed three times with H2O and once with TBS without Tween
20. Membranes were then blocked for 1h in TBS supplemented
with 5% skim milk and probed with the primary antibody for 1h.
Membranes were washed three times with TBS and incubated with
the horseradish peroxidase-bound secondary antibody for 1h at
room temperature. Membranes were washed three times with TBS
and bands were visualised with chemoluminescence POD or Lumi-
light
þ (Roche Diagnostics, Basel, Switzerland). All experiments
were performed three times.
Confocal laser microscopy
The intracellular localisation of Fas in the cell lines was determined
with confocal laser microscopy. Cells were washed cells once with
RPM3 1640 medium 10% FCS. Glass slides were coated with 0.1%
poly-L-lysine and dried at room temperature. A volume of 50mlo f
4 10
5 cells/ml were put on glass slides and left to adhere to the
slides for 1h. Cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS: 6.4mM Na2HPO4,1 5m M KH2PO4;
0.14mM NaCl; 2.7mM KC1; pH 7.2) supplemented with 3.3mM
CaCl2 for 15min. Cells were washed twice with PBS and incubated
for 1h with the CHl 1 anti-Fas antibody. After incubation with the
primary antibody, cells were washed twice and incubated with a
FITC coupled rabbit anti-mouse antibody for 30min and washed
twice before they were analysed on a Leica confocal laser
microscope.
Flow cytometry
To determine Fas membrane expression cells were harvested from
the culture medium by centrifugation at 110g for 5min and
washed twice with cold PBS supplemented with 2% FCS and 0.1%
sodium azide. Cells were then incubated for 1h with the PE-
labelled anti-human Fas DX2 antibody, which was diluted 1:10 in
cold PBS supplemented with 2% FCS and 0.1% sodium azide for
1h on ice in the dark and washed twice with cold PBS. Analysis
was performed on a Coulter Elite Flow cytometer (Becton
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software (Verity Software House, Inc., Topsham, ME, USA). Fas
membrane expression was determined as mean fluorescence
intensity (MFI). To study also the effect of indomethacin on Fas
membrane expression, cells were incubated for 24h with
indomethacin. These experiments were performed three times.
Isolation of total cellular RNA, cDNA synthesis and
RT–PCR
RNA was isolated from log phase cultures of the cell lines. Cells
were harvested by centrifugation at 110g for 5min and washed
with PBS. RNA was isolated with the guanidine isothiocyanate
method. An amount of 5mg RNA was treated with 20–100U
DNAse I (Roche Diagnostics Basel, Switzerland) for 30min. Single-
stranded cDNA was synthesised using M-MLV Reverse Transcrip-
tase (Invitrogen Merelbeke, Belgium) and oligo dT primers
according to the manufacturer’s protocol. For RT–PCR 1mlo f
cDNA was used as the target in a total volume of 50ml. Reactions
were performed according to standard protocols using the
following primers and conditions. FasL (290bp, 531C), upstream
50-CCTCCAGGCAGGCACAGTTCTTCC-30 and downstream 50-AT
CTGGCTGGTAGACTCTCG-30; Fas (338bp, 491C), upstream
50-CATGGCTTAGAAGTGGAAAT-30 and downstream 50-ATTTA
TTGCCACTGTTTCAGG-30, FADD (250bp, 541C), upstream 50-AG
CTCAAAGTCTCAGCACACC-30 and downstream 50-TCTGAGT
TCCATGACATCGG-30; Caspase-8 (355bp, 541C), upstream
50-CTGCTTCATCTCTGTATCC-30 and downstream 50-GCAAAG
TGACTGGATGTACC-30; DcR3 (263bp, 621C), upstream 50-AGC
ACGCATCGTGTCCACC-30 and downstream 50-GACGGCACGCTC
ACACTCC-30; FAP-1 (276bp, 541C), upstream 50-GGAGTTAGTC
TAGAAGGAGC-30 and downstream 50-ACTGAATCCTAGACC
TGAGC-30; FLIPlong (262bp, 541C), upstream 50-GAACATCCACA
GAATAGACC-30 and downstream 50-GTATCTCTCTTCAGGT
ATGC-30; FLIPshort (172bp, 541C), upstream 50-GAACATCCACA
GAATAGACC-30 and downstream 50-TTTCAGATCAGGACAATG
GG-30. All experiments were performed three times.
Mutation screening of Fas
DNA was extracted from the cell lines using a standard laboratory
technique. The Fas gene was screened for mutations by denaturing
gradient gel electrophoresis of the extracted DNA. The entire
coding region, including all splice site junctions, was amplified in
10 amplicons using primers and conditions as described earlier
(Gronbaek et al, 1998). The amplicons were electrophoresed in a
9% polyacrylamide denaturing gradient gel containing 5% glycerol
and 20–60% urea-formamide (100% urea-formamide¼7 M urea
and 40% deionised formamide). The gels were stained with
ethidium bromide and photographed under an UV transillumi-
nator.
Apoptosis assay
Cells (1.5 l0
4 per well) were cultured in 96-well plates and
optionally preincubated with 1mgml
 1 cycloheximide for 2h.
Apoptosis was induced by adding the anti-Fas antibody 7C11
(1mgml
 1) for 24h. To determine whether indomethacin induces
apoptosis, cells were incubated with different concentrations of
indomethacin. To investigate whether apoptosis induction with
indomethacin is Fas-mediated, cells were optionally preincubated
with 2mgml
 1 NOK-1 and incubated with indomethacin for 24h
thereafter. Apoptosis was defined as the appearance of apoptotic
bodies and/or chromatin condensation, using a fluorescence
microscope. Results were expressed as the percentage of apoptotic
cells in a culture by counting at least 200 cells per well. All
apoptosis assays were performed three times in two-fold.
Inhibition of indomethacin-induced apoptosis
At 1h prior to indomethacin exposure, cells were incubated with
20mM broad-spectrum caspase inhibitor zVAD-fmk, caspase-8
inhibitor zIETD-fmk or caspase-9 inhibitor zLEHD-fmk (all from
Calbiochem, Breda, The Netherlands). Cells were exposed to the
combination of indomethacin and caspase inhibitor for 24h after
which acridine orange was added and the percentage apoptotic
cells was calculated. Results are expressed as the percentage of
apoptotic cells in a culture by counting at least 200 cells per well.
All apoptosis assays were performed three times in two-fold.
Caspase-3 activation assay
The cleavage assay was carried out in six-well plates according to
Thornberry et al (2000). Activity of caspase-3 was assayed
according to the manufacturer’s instructions using the fluorescence
peptide substrate Ac-DEVD-AFC (Biomol Tebu-bio, Heerhugo-
waard, The Netherlands). Fluorescence from free 7-amino-4-
trifluoromethyl coumarin (AFC) was monitored in a FL600
Fluorimeter Bio-tek plate reader (Beun de Ronde, Abcoude, The
Netherlands) using 380nm excitation and 508nm emission
wavelengths. Relative caspase-3 activity was calculated by the
fluorescence of a sample of treated cells by a sample of untreated
cells. Protein from all samples was isolated to confirm apoptosis
with PARP cleavage on Western blot. Experiments were performed
three times.
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay
The cell lines were cultured in HAM/F12 and DMEM medium
(1:1) (Life Technologies) supplemented with 20% FCS. The effect
of doxorubicin and indomethacin on survival was tested MTT
assay as described previously (Timmer-Bosscha et al, 1989). Cells
were incubated for 4 days at 371C and 5% CO2 in a humidified
environment with a range of indomethacin concentrations and 10
and 2000nM doxorubicin for GLC4 and GLC4-Adr respectively. The
modulating effect of indomethacin (10 and 20mM) and MK-571
(50mM) on cell survival by doxorubicin were also tested in the MTT
assay using continuous incubation. After a 4-day culture period,
MTT (5mgml
 1 in PBS) was added and formazan crystal
production was measured as described previously. Controls
consisted of media without cells (background extinction) and
cells incubated with medium instead of chemotherapeutic agents.
Experiments were performed three times in quadruplicate.
Statistics
All experiments were performed at least three times on different
occasions. Analysis included double-sided nonpaired t-test. A
P-value o0.05 was considered significant.
RESULTS
Differences between the Fas-mediated apoptosis pathway
of GLC4 and GLC4-Adr
The genes encoding the proapoptotic proteins FasL, Fas, FADD,
and caspase-8 were all expressed at the mRNA level in GLC4 and
GLC4-Adr (Figure 1A). The proteins FasL, Fas, FADD, caspase-8,
Bid, caspase-9, caspase-3 and PARP were also present in both cell
lines (Figure 1B). GLC4 contained less Bid and caspase-8 compared
to GLC4-Adr, while there were no differences in the protein
expression of FasL, Fas, FADD, Bax, caspase-9, caspase-10,
caspase-3, and PARP between the two lines (Figure 1B). Mutation
analysis of the entire Fas gene revealed no aberrant patterns in
both cell lines.
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PCR analysis revealed a higher expression of FLIP1, FLIPS and
DcR3 in GLC4-Adr compared to GLC4 (Figure 2A). Western blot
analysis showed no differences in expression of the apoptosis
inhibitors FAP-1, FLIP, Bcl-2, Bcl-XL and XIAP between the cell
lines. The nonspecific anti-XIAP and Bc1-XL, immunoreactive
molecule as indicated (*) served as an internal loading control
(Deveraux et al, 1999, Delhalle et al, 2002) (Figure 2B). There were
also no differences in COX-2 expression (Figure 2B).
Confocal laser microscopy revealed that in both cell lines Fas
was present in the cytoplasm and at the cell membrane (Figure 3).
However, as determined by flow cytometry GLC4-Adr contained
3.1-fold more Fas on the cell membrane than GLC4. MFI were on
average 15.4 in GLC4 and 47.5 in GLC4-Adr.
Anti-Fas antibody induces apoptosis
Functionality of the Fas pathway was tested by exposure to anti-
Fas antibody (24h) and a combination of anti-Fas antibody (24h)
and cycloheximide (2h preincubation). The anti-Fas antibody
alone hardly induced apoptosis. Cotreatment with cycloheximide
largely increased apoptosis in GLC4-Adr (40%) but had almost no
effect in GLC4 (8%) (Figure 4). Caspase-8 activation was used as
intracellular determinants for activation of the Fas pathway and
PARP cleavage as a marker for apoptosis. Surprisingly, no effect of
anti-Fas antibody alone on caspase-8 cleavage was found.
Intermediate cleavage products of caspase-8 (p41/p43) were
detected after exposure to cycloheximide alone or in combination
with anti-Fas antibody in both cell lines (Figure 5). Active caspase-
8 (pi8 product) was especially observed in GLC4-Adr but only after
cotreatment with cycloheximide and anti-Fas antibody. These
FasL, 36 kDa
Fas, 45 kDa
Caspase-3, 32 kDa
BID, 24 kDa
FADD, 24 kDa
PARP, 112 kDa
Bax, 21 kDa
Caspase-8, 55/53 kDa
Caspase-9, 46−48 kDa
FasL
Fas
FADD
Caspase 8
Caspase-10, 55 kDa
A
B
GLC4 GLC4-Adr
GLC4 GLC4-Adr
Figure 1 Basic mRNA and protein expression levels of proapoptotic
proteins in GLC4 and GLC4-Adr in the Fas-mediated apoptosis pathway
were determined at the mRNA level (A) and protein level (B).
Representative examples of three independent experiments are shown.
FAP-1
DcR3
FLIP1
FLIPs
FLIP-L, 55 kDa
FAP-1, 250 kDa
XIAP*, 57 kDa
Bcl-2, 25 kDa
Bcl-xL, 26 kDa
COX-2, 72 kDa
A
B
GLC4 GLC4-Adr
GLC4 GLC4-Adr
Figure 2 Basic mRNA and protein expression levels of antiapoptotic
proteins in GLC4 and GLC4-Adr in the Fas-mediated apoptosis pathway
were determined at the mRNA level (A) and protein level (B).
Representative examples of three independent experiments are shown.
GLC4 GLC4-Adr
Figure 3 Fas localisation in GLC4 and GLC4-Adr determined with the
mouse monoclonal CH11 anti-Fas antibody (Upstate Biotechnology) using
confocal laser microscopy.
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Figure 4 Fas-mediated apoptosis induction. Apoptosis induction in
GLC4 and GLC4-Adr was determined after exposure to medium (stripes),
cycloheximide (white), anti-Fas antibody 1mgml
 1 (grey) or both (black)
using the apoptosis assay. Data represent the mean7s.d. of three
independent experiments (*Po0.05).
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sresults indicate the presence of intracellular inhibitors) of the Fas-
mediated apoptosis pathway, presumably at the level of caspase-8.
Indomethacin induces apoptosis in GLC4-Adr but not in
GLC4
Indomethacin alone had hardly any effect on apoptosis induction
in GLC4 but already induced apoptosis (28%) in GLC4-Adr at 25mM
(Figure 6). GLC4 and GLC4-Adr were exposed to 0, 25, 50 and
100mM indomethacin for 16 and 24h in order to study the
apoptosis-inducing effect of indomethacin in more detail. Cleavage
of caspase-8, Bid and PARP was investigated with Western
blotting. Caspase-8, Bid, caspase-9 and PARP activation in GLC4-
Adr occurred 16h after the addition of 50mM indomethacin. In
GLC4-Adr 100mM indomethacin induced clearly detectable levels of
activated caspase-8 (p 18) as well as massive cleavage of full-length
caspase-8 and PARP. Indomethacin more effectively induced
caspase-8 activation than the combination of anti-Fas antibody
and cycloheximide in GLC4-Adr. However, even at these high
indomethacin concentrations, no activation of caspase-8, Bid and
PARP was observed in GLC4 (Figure 7A).
To further investigate the mechanism by which indomethacin
induces apoptosis, GLC4 and GLC4-Adr cells were exposed to 25
and 50mM indomethacin and protein expression levels of anti-
apoptotic Bcl-2 family members were analysed. No changes in Bcl-
2, Bcl-XS/L or Mcl-1 expression were observed in both cell lines
(Figure 7B).
To determine more quantitatively the effect of various drug
combinations on apoptosis in GLC4-Adr, caspase-3 activation was
measured with the DEVD-AFC cleavage assay. Doxorubicin alone
showed minimal caspase-3 activation. Doxorubicin in combination
with anti-Fas antibody had a slightly additive effect on caspase-3
activation. The combination of doxorubicin with indomethacin
was, however, the most effective combination to induce caspase-3
activation (Figure 8).
Indomethacin induces caspase-8 and caspase-9 activation
independently from Fas
The nature of the indomethacin-induced caspase-8 activation was
further investigated. Apoptosis induction in GLC4-Adr could not
be prevented by preincubation with the anti-FasL NOK-1 antibody
(data not shown). This means that indomethacin-induced
apoptosis is not caused by autocrine or paracrine Fas/FasL
interactions. In addition, indomethacin at a concentration of
50mM for 24h did not affect Fas membrane expression (results not
shown).
Exposure of GLC4-Adr cells to indomethacin in combination
with caspase inhibitors revealed that indomethacin-induced
apoptosis is reduced when cells are exposed to indomethacin in
combination with zIETD-fmk, zLEHD-fmk or zVAD-fmk activity.
The caspase-8-specific inhibitor zIETD-fmk and the caspase-9-
specific inhibitor zLEHD-fmk reduced indomethacin-induced
apoptosis by 58 and 44%, respectively, the broad-spectrum caspase
inhibitor zVAD-fmk by 84% (Figure 9).
Modulation of chemotherapy-induced growth inhibition
by indomethacin
To investigate growth inhibition after exposure to indomethacin
and doxorubicin the MTT assay was used. GLC4-Adr cells are
190.6716.2 times more resistant to doxorubicin as compared to
GLC4. Two relatively nontoxic concentrations of indomethacin (10
and 20mM) that induced some caspase activation in GLC4-Adr,
were used in combination with doxorubicin in an MTT assay. A
dose of 10 and 20mM of indomethacin induced, respectively, 1 and
2% growth inhibition in GLC4, and respectively 15 and 17% in
GLC4-Adr. In the presence of 20mM indomethacin there was no
effect on doxorubicin sensitivity in GLC4, while a 2.7-fold increase
in doxorubicin sensitivity was observed in GLC4-Adr (Table 1).
Indomethacin, like doxorubicin, is also a substrate for the MRPl
drug efflux pump, which is overexpressed in GLC4-Adr. We
observed a similar increase in doxorubicin sensitivity comparing
the effect of indomethacin with the effect of MK-571, a well-
established inhibitor of MRPl, in the MTT assay (Table 1).
DISCUSSION
This is the first study that illustrates the effective circumvention of
doxorubicin resistance by indomethacin-induced activation of the
1gml−1 cycloheximide
1gml−1 anti-Fas antibodies
−+
+ +
−+
−−
GLC4
GLC4-Adr
PARP
113
kDa
113  PARP
89
Caspase-8
55/53
43/41
55/53
43/41
18
18
Caspase-8
Figure 5 Fas-mediated caspase cleavage. PARP and caspase-8 cleavage
were determined after exposing GLC4 and GLC4-Adr to anti-Fas antibody
for 24h and cycloheximide for 24 and 2h preincubation. Representative
example of three independent experiments.
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Figure 6 Indomethacin-mediated apoptosis. Apoptosis induction in
GLC4 and GLC4-Adr was determined after exposure to different
concentrations of indomethacin for 48h.
Indomethacin circumvents doxorubicin resistance
DJA de Groot et al
1463
British Journal of Cancer (2005) 92(8), 1459–1466 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sdeath receptor apoptosis pathway in a doxorubicin-resistant SCLC
cell line independent of Fas.
Fas-mediated apoptosis could only be induced in GLC4-Adr but
not in GLC4 in the presence of the protein synthesis inhibitor
cycloheximide, demonstrating that the death receptor-mediated
apoptosis pathway is functional in the chemotherapy resistant cell
line when a cellular block is removed. Interestingly, indomethacin
induced apoptosis in GLC4-Adr but not in GLC4 in the absence of
cycloheximide. No marked intensity differences were observed for
pro- and antiapoptotic proteins involved in the mitochondrial
apoptosis pathway. In contrast, several proapoptotic proteins
important for the death receptor apoptosis pathway were higher
expressed in the doxorubicin-resistant cell line GLC4-Adr com-
pared to GLC4. For instance, the Fas-membrane expression was
3.1-fold higher in GLC4-Adr compared to the parental cell line. The
higher Fas membrane expression may be due to the repetitive
incubation with doxorubicin. It may also serve to facilitate a
growth advantage to GLC4-Adr as was demonstrated in several
Fas-positive tumour cell lines (Owen-Schaub et al, 1994; Siegel
et al, 2000). The fact that the difference in Fas membrane
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Figure 7 (A) Indomethacin-induced activation of the death receptor
apoptosis pathway. Caspase-8, Bid and PARP cleavage were determined
after exposing GLC4 and GLC4-Adr to 0, 25, 50 and 100mM indomethacin
for 16 and 24h. Representative example of three experiments are shown.
(B) Expression of Bcl-2, Bc1-XS/L and Mcl-1 after 24h of 25 and 50mM
indomethacin exposure.
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Figure 8 Effects of modulators on caspase-3 activation in GLC4-Adr
after 48h of exposure to. (1) medium, (2) indomethacin (25mM), (3)
doxorubicin (3mM), (4) anti-Fas antibody (1mgml
 1), (5) anti-Fas antibody
and doxorubicin (3mM), (6) indomethacin (25mM) and doxorubicin (3mM).
Exposure to the anti-Fas antibody was only for the last 24h. Data represent
the mean7s.d. of three independent experiments (*Po0.05).
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Figure 9 Inhibition of indomethacin-induced apoptosis. Apoptosis
induction in GLG4-Adr after exposure to 50mM indomethacin (grey) or
0mM indomethacin (black) in combination with the caspase-8 inhbitor
zIETD-fmk, the caspase-9 inhibitor zLEHD or the broad-spectrum caspase
inhibitor zVAD-fmk for 24h.
Table 1 A 50% inhibiting dose in the MTT assay (mM) of doxorubicin and
doxorubicin in combination with indomethacin (10 and 20mM) in GLC4 and
GLC4-Adr
GLC4 GLC4-Adr
Doxorubicin (mM) 0.01470.001 2.75070.050
Doxorubicin+indomethacin (10mM) 0.01170.002 1.40370.203*
Doxorubicin+indomethacin (20mM) 0.01270.002 1.00370.179*
Doxorubicin+MK571 (50mM) 0.01470.002 0.74370.121*
Data represent the mean7s.d. of three independent experiments (*Po0.01).
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sexpression does not correlate with the Fas expression in total cell
lysates may be due to a different distribution of Fas, cytoplasmic
and on the cell membrane, as was described in prostate carcinoma
cell lines and neuroblastoma cell lines (Fulda et al, 1997; Usla et al,
1997; Bennett et al, 1998; Sodeman et al, 2000). The expression
levels of the proapoptotic proteins caspase-8 and Bid were also
elevated in GLC4-Adr compared to GLC4. Bid has been described to
transport and recycle mitochondrial membrane phospholipids
(Esposti et al, 2001). Since doxorubicin has toxic properties
towards mitochondrial membranes, increased expression of Bid in
GLC4-Adr may be an additional resistance mechanism. The
sensitivity of GLC4-Adr to Fas-mediated apoptosis, in the presence
of cycloheximide, as compared to GLC4 can therefore be due to the
higher Fas-membrane levels as well as elevated expression levels of
caspase-8 and Bid or a combination of these factors. Anti-Fas
antibody alone induced minimal caspase-3 activation which was
only slightly increased by combining it with doxorubicin in GLC4-
Adr. Owing to the limited modulatory effects of doxorubicin on
Fas-mediated apoptosis an alternative was sought.
The NSAID indomethacin has been identified as an apoptosis-
inducing agent in different in vivo models and among the several
mechanisms involved it can induce caspase-3-mediated apoptosis
(Fujii et al, 2000; Kim et al, 2000; Sanchez-Alcazar et al, 2003). The
apoptosis-inducing effect of indomethacin in GLC4-Adr is,
however, not based on Fas/FasL interaction. Indomethacin did
not affect Fas membrane expression and apoptosis is not decreased
when cells are pretreated with an inhibiting anti-FasL antibody
prior and during indomethacin exposure. Indomethacin alone
induced extensive apoptosis in GLC4-Adr with activation of
caspase-8, caspase-9 and PARP cleavage even at low doses. This
did not occur in GLC4. The apoptosis-inducing effect of
indomethacin will therefore most likely be due to a Fas receptor-
independent effect on the death receptor-apoptosis pathway.
However, we cannot exclude the involvement of other death
receptors. Inhibition of either caspase-8 or caspase-9 by zIETD-
fmk and zLEHD-fink, respectively, decreased indomethacin-
induced apoptosis. Therefore, indomethacin-mediated apoptosis
induction in the GLC4 cell lines depends on a functional
mitochondrial apoptosis pathway, which is probably absent in
GLC4 due to the decreased Bid expression. Indomethacin, however,
did not decrease expression of Bcl-2, Bcl-XS/L or Mcl-1 in GLC4 or
GLC4-Adr which is in contrast to results described for lung
adenocarcinoma cell lines (Lin et al, 2001). The feet that
indomethacin can activate caspase-8, Bid and caspase-9 in GLC4-
Adr makes it a good alternative for agonistic anti-Fas antibody.
Indomethacin added to doxorubicin largely increased doxorubicin
effects on caspase-3 activation and cytotoxicity in GLC4-Adr cells.
Indomethacin, like doxorubicin, is a substrate for the MRP1 drug
efflux pump, which is overexpressed in GLG4-Adr (Versantvoort
et al, 1995; Draper et al, 1997; Touhey et al, 2002). Therefore, a
subsequent increase in cellular doxorubicin concentration by
indomethacin may have partly played a role. Other mechanisms by
which indomethacin might induce apoptosis are increased
glutathione extrusion mediated by MRP1 (Trompier et al, 2004)
or increased ATP consumption by MRP1 ATPase activity in
analogy to the observed verapamil-induced ATP consumption in
P-glycoprotein-overexpressing cells (Broxterman et al, 1989).
The role of indomethacin in modulation of doxorubicin toxicity,
however, cannot completely be explained by the MRP1 inhibitory
effect. MK-571 is a far more effective inhibitor of MRP1-mediated
drug efflux than indomethacin (Bagrij et al, 2001). Despite the
similar fold of doxorubicin sensitisation with either drug, this
suggests that the observed effect of indomethacin on doxorubicin
sensitivity is due to an increase in drug accumulation as well as
MRP1-dependent or independent caspase activation in GLQ-Adr
cells.
Interestingly, the NSAIDs have recently caught much attention
in the treatment of tumours in combination with chemotherapy to
potentiate their effect (Gupta and DuBois, 2001). The first clinical
report on a combination of celecoxib, an NSAID and selective
cyclooxygenase-2 inhibitor, with chemotherapy appeared (Altorki
et al, 2003). It showed an enhanced response to preoperative
paclitaxel and carboplatin in early-stage non-small-cell lung
cancer. This approach in SCLC may also be of interest not only
because of Cox-2 inhibition but also because of the effect observed
by us on the alternative apoptotic route compared to the route
used by chemotherapy. The observed extensive potentiation of
doxorubicin-induced inhibition of cell survival at achievable
clinical doses indomethacin (Gupta and DuBois, 2001), deserves
testing in the clinic. The potential effect of these concentrations of
indomethacin on other chemotherapeutic drugs requires further
testing in preclinical models.
Overall, it can be concluded that indomethacin increases the
cytotoxic activity of doxorubicin in a doxonibicin-resistant SCLC
cell line partly via the death receptor apoptosis pathway,
independent of Fas.
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